Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1980 Oct;41(2):289–296.

Presence of a tumour-inhibiting factor (TIF) in sera from normal but not tumour-bearing mice.

B S Kim, D K Chin
PMCID: PMC1458185  PMID: 7002770

Abstract

Some plasmacytomas produce myeloma proteins with known antibody specificities and the secretion of these proteins by individual tumour cells can be determined using haemolytic plaque assay. After a 3 day culture of mouse plasmacytoma cells in medium containing 10% normal mouse serum, the number of plaques was reduced to less than 10% when compared to that of tumour cells incubated with either foetal calf serum or normal rabbit serum. However, tumour cells incubated with sera from mice bearing TEPC-15, McPC-603, or MOPC-315 plasmacytomas displayed control levels of plaques. The production of plaques paralleled the viability of tumour cells suggesting that the reduction of plaque formation is due to the decreased viable cell number. The tumour-inhibiting activity was recovered from the fraction of apparent molecular weight of 300,000-400,000 after a partial purification using an agarose (A 0.5 M) column. This fraction, however, did not suppress in vitro induction of antibody production. Kinetic experiments using sera obtained sequentially from individual mice receiving either TEPC-15 or MOPC-315 plasmacytomas further indicated that the tumour-inhibiting activity is severely reduced during a 2 week period after tumour inoculation. The inhibition of tumour cells did not appear to be specific since tumour cells of three plasmacytomas (TEPC-15, MOPC-167 and MOPC-315), a mastocytoma (P815) and a lymphoma (EL-4) displayed a similar susceptibility to normal serum.

Full text

PDF
289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cosenza H., Köhler H. Specific suppression of the antibody response by antibodies to receptors. Proc Natl Acad Sci U S A. 1972 Sep;69(9):2701–2705. doi: 10.1073/pnas.69.9.2701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Herberman R. B., Aoki T. Immune and natural antibodies to syngeneic murine plasma cell tumors. J Exp Med. 1972 Jul 1;136(1):94–111. doi: 10.1084/jem.136.1.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Herberman R. B., Djeu J., Kay H. D., Ortaldo J. R., Riccardi C., Bonnard G. D., Holden H. T., Fagnani R., Santoni A., Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979;44:43–70. doi: 10.1111/j.1600-065x.1979.tb00267.x. [DOI] [PubMed] [Google Scholar]
  4. Jerne N. K., Nordin A. A. Plaque Formation in Agar by Single Antibody-Producing Cells. Science. 1963 Apr 26;140(3565):405–405. doi: 10.1126/science.140.3565.405. [DOI] [PubMed] [Google Scholar]
  5. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975 Feb;5(2):112–117. doi: 10.1002/eji.1830050208. [DOI] [PubMed] [Google Scholar]
  6. Kim B. S., Rowley D. A., Mallat L. Specific antigens inhibit plasmacytoma cells bearing phosphorylcholine-binding myeloma proteins. Cell Immunol. 1978 Dec;41(2):286–293. doi: 10.1016/0008-8749(78)90226-5. [DOI] [PubMed] [Google Scholar]
  7. Law L. W. Studies of tumor antigens and tumor-specific immune mechanisms in experimental systems. Transplant Proc. 1970 Mar;2(1):117–132. [PubMed] [Google Scholar]
  8. MOWBRAY J. F. Ability of large doses of an alpha-2 plasma protein fraction to inhibit antibody production. Immunology. 1963 May;6:217–225. [PMC free article] [PubMed] [Google Scholar]
  9. Martin W. J., Martin S. E. Naturally occurring cytotoxic anti-tumour antibodies in sera of congenitally athymic (nude) mice. Nature. 1974 Jun 7;249(457):564–565. doi: 10.1038/249564a0. [DOI] [PubMed] [Google Scholar]
  10. Mengersen R., Schick R., Kölsch E. Correlation of "sneaking through" of tumor cells with specific immunological impairment of the host. Eur J Immunol. 1975 Aug;5(8):532–537. doi: 10.1002/eji.1830050805. [DOI] [PubMed] [Google Scholar]
  11. Miller F. Serum-derived immunosuppressive substances. I. Partial purification and range of action. Transplantation. 1976 Mar;21(3):179–187. doi: 10.1097/00007890-197603000-00001. [DOI] [PubMed] [Google Scholar]
  12. Mishell R. I., Dutton R. W. Immunization of normal mouse spleen cell suspensions in vitro. Science. 1966 Aug 26;153(3739):1004–1006. doi: 10.1126/science.153.3739.1004. [DOI] [PubMed] [Google Scholar]
  13. Murgita R. A., Tomasi T. B., Jr Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response. J Exp Med. 1975 Feb 1;141(2):269–286. doi: 10.1084/jem.141.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rittenberg M. B., Pratt K. L. Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen. Proc Soc Exp Biol Med. 1969 Nov;132(2):575–581. doi: 10.3181/00379727-132-34264. [DOI] [PubMed] [Google Scholar]
  15. Röllinghoff M., Rouse B. T., Warner N. L. Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors. J Natl Cancer Inst. 1973 Jan;50(1):159–172. doi: 10.1093/jnci/50.1.159. [DOI] [PubMed] [Google Scholar]
  16. Veit B., Michael J. G. Characterization of an immunosuppressive factor present in mouse serum. J Immunol. 1973 Aug;111(2):341–351. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES